Kemptville, Ontario, June 26, 2024 – Cannabis Orchards Inc. is thrilled to announce that it has been awarded a non-repayable contribution of $404,305 from the AgriScience Program – Projects Component, from Agriculture and Agri-Food Canada’s AgriScience Program, under the Sustainable Canadian Agricultural Partnership. This significant funding supports Cannabis Orchards’ groundbreaking project titled “Minor Cannabinoids, Major Advancements: Polyploidization and Enrichment of Cannabinoid Hemp,” with a total project cost of $808,610.
The project aims to develop seedless triploid hemp lines for cannabidiol (CBD) and minor cannabinoids such as cannabigerol (CBG) and cannabichromene (CBC). Minor cannabinoids are still rare in the market despite their demonstrated potential for various therapeutic applications. By developing novel triploid hemp lines, Cannabis Orchards seeks to create new markets and maximize yields and profits for hemp farmers, providing them with infertile triploid seed varieties that prevent the detrimental effects of pollination and enhance desirable traits.
Dr. Jamie Ghossein, CEO of Cannabis Orchards, commented, “This funding from the AgriScience Program is a significant recognition of our efforts to advance cannabinoid research. Our project will enable the development of seedless triploid hemp varieties, addressing the scarcity of minor cannabinoids and opening new avenues for therapeutic development while maximizing yield for farmers. By preventing unwanted pollination and enhancing desirable traits, we can ensure higher yields and more consistent quality, benefiting farmers, consumers, and researchers alike.”
The project, which commenced on January 1, 2024, and will conclude on December 31, 2026, focuses on the plant breeding of high minor cannabinoid hemp varieties, specifically for cannabigerol and cannabichromene. Additionally, the project includes the development of polyploid hemp plants, aiming to generate triploid plants with elevated levels of minor cannabinoids and desirable traits such as infertility.
Dr. Ghossein further added, “The potential of minor cannabinoids in therapeutic applications is vast, yet they remain underutilized due to their scarcity. Our research and development efforts are dedicated to unlocking this potential, ultimately providing more effective treatment options for a variety of conditions, and opening new commercialization opportunities for farmers and the Canadian cannabinoid industry.”
Contact Information:
Rachael Cranston
Sales Department
Cannabis Orchards
Email: sales@cannabisorchards.ca
Website: www.cannabisorchards.ca
About Cannabis Orchards
Cannabis Orchards Inc. is an inventive, research-driven, and proudly Canadian company focused on furthering the development and commercialization of novel cannabinoids and therapeutics. The company leads research into the development of new hemp varieties with minor cannabinoid content and their applications in clinical settings. Cannabis Orchards’ products are highly sought after by Licensed Processors, research institutes, and pharmaceutical companies. For more information on Cannabis Orchards Inc., visit www.cannabisorchards.ca.
Comments